Pradžia › Šizofrenija › Ilinoisas
Šizofrenija klinikiniai tyrimai Ilinoisas
26 tyrimai dėl Šizofrenija ieško dalyvių vietose Ilinoisas.
Miestai Ilinoisas
Oficialus tyrimo tekstas (anglų kalba)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- The University of Chicago, Chicago
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 18 iki 59 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
Renkami dalyviai1 fazė
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2026-09-28 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-28 · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
Renkami dalyviai3 fazė
Amžius nuo 5 iki 17 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07114874A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Renkami dalyviai3 fazė
Amžius nuo 5 iki 17 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
Renkami dalyviai2 fazė
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-09 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Renkami dalyviai3 fazė
Amžius nuo 13 iki 17 · Visoms lytims · Atnaujinta 2026-09-04 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
Renkami dalyviai1 fazė
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2026-09-02 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-01 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
Renkami dalyviai3 fazė
Amžius nuo 10 iki 17 · Visoms lytims · Atnaujinta 2026-08-14 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-07-29 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-07-27 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 40 · Visoms lytims · Atnaujinta 2026-07-20 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
Renkami dalyviai2 fazė
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2026-06-23 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
Renkami dalyviai4 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-06-03 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
Renkami dalyviai4 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-05-11 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 40 · Visoms lytims · Atnaujinta 2026-03-10 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-03-06 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-01-12 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
Renkami dalyviai2 fazė
Amžius nuo 21 iki 55 · Visoms lytims · Atnaujinta 2025-12-26 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
Renkami dalyviai3 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2024-12-19 · NCT05184335Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.